title: CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
abstract: OBJECTIVE
  A number of studies have evaluated the association between cytochrome P450 2E1 (CYP2E1) RsaI/PstI polymorphism and the risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, the results were inconsistent. We conducted a meta-analysis  to clarify the role of this polymorphism in ATDILI.
  
  
  METHODS
  Two authors independently searched the PubMed, Medline, EMBASE and Chinese National Knowledge Infrastructure databases for studies on the association of CYP2E1 RsaI/PstI polymorphism with risk of ATDILI. Summary odds ratios  (ORs) with their corresponding 95% confidence intervals (CIs) were calculated.
  
  
  RESULTS
  The combined results showed that the CYP2E1 c1/c1 genotype was associated with increased ATDILI risk compared to variant genotypes (c1/c2+c2/c2) (OR 1.36, 95%CI 1.09-1.69). When stratifying  for study population, statistically significant results were observed in Chinese (OR 1.47, 95%CI 1.12-1.92) and Korean populations (OR 1.85, 95%CI 1.04-3.30). In comparison with CYP2E1 c1/c2 or c2/c2 with rapid/intermediate acetylators, the risk of ATDILI increased from  1.88 (95%CI 1.14-3.09) for CYP2E1 c1/c1 with rapid/intermediate acetylators to 6.44 (95%CI 3.47-11.97) for CYP2E1 c1/c1 with slow acetylators.
  
  
  CONCLUSIONS
  This meta-analysis suggests that CYP2E1 RsaI/PstI polymorphism may affect susceptibility to ATDILI,  particularly among Chinese and Korean populations.
authors.affiliation: Department of General Toxicology, National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China.
authors.forename: R
authors.initials: R
authors.lastname: Deng
authors.forename: T
authors.initials: T
authors.lastname: Yang
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: N
authors.initials: N
authors.lastname: Tang
mesh_terms: D000107:Acetylation; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000378:metabolism; D044466:Asian People / Q000235:genetics; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000208:ethnology / Q000209:etiology* / Q000235:genetics; D016009:Chi-Square Distribution; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000995:Antitubercular Agents; D019392:Cytochrome P-450 CYP2E1